The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Minghua Zheng - One of the best experts on this subject based on the ideXlab platform.
-
metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients
Journal of Gastroenterology and Hepatology, 2020Co-Authors: Kenneth I Zheng, Xiaobo Wang, Ting Yao Wang, Yong Ping Chen, Jacob George, Minghua ZhengAbstract:BACKGROUND & AIMS: Coronavirus disease 2019 (COVID-19) has attracted increasing worldwide attention. While diabetes is known to aggravate COVID-19 severity, it is not known whether non-diabetic patients with metabolic dysfunction are also more prone to more severe disease. We investigated the association of metabolic associated fatty liver disease (MAFLD) to COVID-19 severity in non-diabetic patients. METHODS: The study cohort comprised 65 patients with- (i.e. cases) and 65 patients without MAFLD (i.e. controls). Each case was randomly matched with one control by sex (1:1) and age (±5 years). The association between presence of MAFLD (as exposure) and COVID-19 severity (as the outcome) was assessed by binary logistic regression analysis. RESULTS: In non-diabetic patients with COVID-19, the presence of MAFLD was associated with a 4-fold increased risk of severe COVID-19; the risk increased with increasing numbers of metabolic risk factors. The association with COVID-19 severity persisted after adjusting for age, sex and coexisting morbid conditions. CONCLUSIONS: Health care professionals caring for non-diabetic patients with COVID-19 should be cognizant of the increased likelihood of severe COVID-19 in patients with metabolic associated fatty liver disease.
Christine Verellendumoulin - One of the best experts on this subject based on the ideXlab platform.
-
isolated polycystic liver disease as a distinct genetic disease unlinked to polycystic kidney disease 1 and polycystic kidney disease 2
Hepatology, 1996Co-Authors: Yves Pirson, N Lannoy, D Peters, Andre Geubel, Jeanfrancois Gigot, M Breuning, Christine VerellendumoulinAbstract:Polycystic liver disease (PLD) is proven to occur either sporadically or in association with autosomal dominant polycystic kidney disease (ADPKD), whereas the existence of an isolated (i.e., without any kidney cyst) familial form is disputed. We describe a family with definitely isolated PLD transmitted through three generations and exclude the linkage of the disease to the genetic markers of PKD1 and PKD2, the two main loci responsible for ADPKD. These findings strongly support the existence of PLD as a genetic disease distinct from the known forms of ADPKD.
Leroy E Rabbani - One of the best experts on this subject based on the ideXlab platform.
-
coronavirus disease 2019 covid 19 and cardiovascular disease
Circulation, 2020Co-Authors: K J Clerkin, J Fried, J Raikhelkar, G Sayer, Jan M Griffin, A Masoumi, Sneha S Jain, Daniel Burkhoff, Deepa Kumaraiah, Leroy E RabbaniAbstract:Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and >3 000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute respiratory syndrome coro...
Yves Pirson - One of the best experts on this subject based on the ideXlab platform.
-
isolated polycystic liver disease as a distinct genetic disease unlinked to polycystic kidney disease 1 and polycystic kidney disease 2
Hepatology, 1996Co-Authors: Yves Pirson, N Lannoy, D Peters, Andre Geubel, Jeanfrancois Gigot, M Breuning, Christine VerellendumoulinAbstract:Polycystic liver disease (PLD) is proven to occur either sporadically or in association with autosomal dominant polycystic kidney disease (ADPKD), whereas the existence of an isolated (i.e., without any kidney cyst) familial form is disputed. We describe a family with definitely isolated PLD transmitted through three generations and exclude the linkage of the disease to the genetic markers of PKD1 and PKD2, the two main loci responsible for ADPKD. These findings strongly support the existence of PLD as a genetic disease distinct from the known forms of ADPKD.
Kenneth I Zheng - One of the best experts on this subject based on the ideXlab platform.
-
metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients
Journal of Gastroenterology and Hepatology, 2020Co-Authors: Kenneth I Zheng, Xiaobo Wang, Ting Yao Wang, Yong Ping Chen, Jacob George, Minghua ZhengAbstract:BACKGROUND & AIMS: Coronavirus disease 2019 (COVID-19) has attracted increasing worldwide attention. While diabetes is known to aggravate COVID-19 severity, it is not known whether non-diabetic patients with metabolic dysfunction are also more prone to more severe disease. We investigated the association of metabolic associated fatty liver disease (MAFLD) to COVID-19 severity in non-diabetic patients. METHODS: The study cohort comprised 65 patients with- (i.e. cases) and 65 patients without MAFLD (i.e. controls). Each case was randomly matched with one control by sex (1:1) and age (±5 years). The association between presence of MAFLD (as exposure) and COVID-19 severity (as the outcome) was assessed by binary logistic regression analysis. RESULTS: In non-diabetic patients with COVID-19, the presence of MAFLD was associated with a 4-fold increased risk of severe COVID-19; the risk increased with increasing numbers of metabolic risk factors. The association with COVID-19 severity persisted after adjusting for age, sex and coexisting morbid conditions. CONCLUSIONS: Health care professionals caring for non-diabetic patients with COVID-19 should be cognizant of the increased likelihood of severe COVID-19 in patients with metabolic associated fatty liver disease.